$5.35
-0.26[-4.63%]
At close: Apr 19
$5.94
0.5900[11.03%]
After Hours: 5:47PM EDT
Aprea Therapeutics
(NASDAQ:APRE)Aprea Therapeutics Stock (NASDAQ:APRE), Analyst Ratings, Price Targets, Predictions
Aprea Therapeutics Inc has a consensus price target of $7, established from looking at the 16 latest analyst ratings. The last 3 analyst ratings were released from Wedbush, HC Wainwright & Co., and HC Wainwright & Co. on March 27, 2024, March 26, 2024, and November 1, 2023. With an average price target of $17 between Wedbush, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 186.20% upside for Aprea Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
HC Wainwright & Co.
Maxim Group
HC Wainwright & Co.
RBC Capital
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Aprea Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/27/2024 | APRE | Buy Now | Aprea Therapeutics | $5.94 | 85.19% | Wedbush | Robert Driscoll | $9 → $11 | Maintains | Outperform | Get Alert |
| 03/26/2024 | APRE | Buy Now | Aprea Therapeutics | $5.94 | 236.7% | HC Wainwright & Co. | Joseph Pantginis | $20 → $20 | Maintains | Buy | Get Alert |
| 11/01/2023 | APRE | Buy Now | Aprea Therapeutics | $5.94 | 236.7% | HC Wainwright & Co. | Joseph Pantginis | → $20 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | APRE | Buy Now | Aprea Therapeutics | $5.94 | 236.7% | HC Wainwright & Co. | Joseph Pantginis | → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | APRE | Buy Now | Aprea Therapeutics | $5.94 | 236.7% | HC Wainwright & Co. | Joseph Pantginis | → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | APRE | Buy Now | Aprea Therapeutics | $5.94 | 236.7% | HC Wainwright & Co. | Joseph Pantginis | → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/10/2023 | APRE | Buy Now | Aprea Therapeutics | $5.94 | 169.36% | Maxim Group | Jason McCarthy | → $16 | Initiates | → Buy | Get Alert |
| 10/10/2022 | APRE | Buy Now | Aprea Therapeutics | $5.94 | -49.49% | HC Wainwright & Co. | Joseph Pantginis | → $60 | Assumes | → Buy | Get Alert |
| 07/08/2022 | APRE | Buy Now | Aprea Therapeutics | $5.94 | -49.49% | Wedbush | Robert Driscoll | → $60 | Initiates | → Outperform | Get Alert |
| 03/16/2022 | APRE | Buy Now | Aprea Therapeutics | $5.94 | -66.33% | HC Wainwright & Co. | Andrew Fein | $80 → $40 | Maintains | Neutral | Get Alert |
| 03/16/2022 | APRE | Buy Now | Aprea Therapeutics | $5.94 | -32.66% | RBC Capital | Gregory Renza | $100 → $80 | Maintains | Sector Perform | Get Alert |
| 08/20/2021 | APRE | Buy Now | Aprea Therapeutics | $5.94 | — | JP Morgan | Jessica Fye | — | Downgrade | Neutral → Underweight | Get Alert |
| 08/16/2021 | APRE | Buy Now | Aprea Therapeutics | $5.94 | — | Berenberg | Esther Hong | — | Downgrade | Buy → Hold | Get Alert |
| 08/16/2021 | APRE | Buy Now | Aprea Therapeutics | $5.94 | -32.66% | HC Wainwright & Co. | Andrew Fein | — | Maintains | Neutral | Get Alert |
| 08/13/2021 | APRE | Buy Now | Aprea Therapeutics | $5.94 | -15.82% | RBC Capital | Gregory Renza | — | Maintains | Sector Perform | Get Alert |
| 08/13/2021 | APRE | Buy Now | Aprea Therapeutics | $5.94 | -49.49% | Morgan Stanley | Jeffrey Hung | — | Downgrade | Equal-Weight → Underweight | Get Alert |
FAQ
What is the target price for Aprea Therapeutics (APRE)?
The latest price target for Aprea Therapeutics (NASDAQ: APRE) was reported by Wedbush on March 27, 2024. The analyst firm set a price target for $11.00 expecting APRE to rise to within 12 months (a possible 105.61% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aprea Therapeutics (APRE)?
The latest analyst rating for Aprea Therapeutics (NASDAQ: APRE) was provided by Wedbush, and Aprea Therapeutics maintained their outperform rating.
When was the last upgrade for Aprea Therapeutics (APRE)?
There is no last upgrade for Aprea Therapeutics.
When was the last downgrade for Aprea Therapeutics (APRE)?
The last downgrade for Aprea Therapeutics Inc happened on August 20, 2021 when JP Morgan changed their price target from N/A to N/A for Aprea Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Aprea Therapeutics (APRE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aprea Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aprea Therapeutics was filed on March 27, 2024 so you should expect the next rating to be made available sometime around March 27, 2025.
Is the Analyst Rating Aprea Therapeutics (APRE) correct?
While ratings are subjective and will change, the latest Aprea Therapeutics (APRE) rating was a maintained with a price target of $9.00 to $11.00. The current price Aprea Therapeutics (APRE) is trading at is $5.35, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.